Empagliflozin effect on supraventricular arrhythmias
- Conditions
- Supraventricular arrhythmias.Atrial fibrillation and flutter
- Registration Number
- IRCT20240116060704N1
- Lead Sponsor
- Bagheiat-allah University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Age more than 18 years
Diagnosis of heart failure based on echocardiography
Having an ICD for more than 3 months before starting participation in the study
Obtaining the patient's informed consent
Using SGLT2 inhibitors before starting participation in the study
New York Heart Association function class IV heart failure
Renal dysfunction (eGFR < 20 mL/min/1.73 m2 ) or dialysis
Hepatic dysfunction (AST or ALT > 3 times higher than upper limit of normal)
Body mass index < 18.5 kg/m2
Pregnancy or lactation
Patients with the following events within 3 months before the eligibility test: alteration of the anti-arrhythmic drug, catheter ablation for supraventricular arrhythmia, coronary revascularization, open-heart surgery, development of coronary artery disease, stroke or transient ischemic stroke, seizure, infection requiring hospitalization
Other commodities, including various infections, major surgery, type 1 diabetes, pituitary or adrenal insufficiency, cancer
Single chamber ICDs or ICDs unable to record atrial arrhythmias
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of the supraventricular arrhythmias (atrial fibrillation and flutter). Timepoint: During the three months before the intervention and during the three months after the intervention. Method of measurement: ICD (implantable cardioverter-defibrillator) record.
- Secondary Outcome Measures
Name Time Method